ERBB2 and neoplasm: In this context, the “APT regimen”, i.e., 12 weeks of paclitaxel in combination with a 1-year course of trastuzumab, has been widely adopted in the global guidelines as the standard of care for low-risk patients, even if the main critical issue is the absence of the option for post-neoadjuvant therapy if the initially low-risk HER2-positive tumor becomes a high-risk tumor postoperatively [59,60,61,62,63,64,65].